Low-dose treatment strategies. 1986

T Van Putten, and S R Marder

Dose-comparison studies in chronic, continuously hospitalized patients show that megadoses of antipsychotic drugs are reasonably well tolerated. These findings, together with dose-comparison studies in acute patients, support the notion (and current practice) that the therapeutic index of antipsychotic drugs is wide. Recent work with outpatients indicates that fluphenazine decanoate 5 mg (versus 25 mg) every 2 weeks is effective for at least the first year. In addition, patients report feeling better when they take the lower dose. A dose-comparison study with haloperidol in newly admitted patients indicates that a 20 mg daily dose has neurotoxic effects. A similar dose-comparison study with oral fluphenazine indicates that a 5 mg daily dose is efficacious over a 3-week period. Thus, both inpatients and outpatients can be managed on doses that were formerly regarded as homeopathic. Patients taking low doses have fewer side effects (particularly less akinesia) and probably fewer dysphoric emotions than patients taking high doses, although they improve at a slower rate.

UI MeSH Term Description Entries
D008297 Male Males
D011618 Psychotic Disorders Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) Psychoses,Psychosis, Brief Reactive,Schizoaffective Disorder,Schizophreniform Disorders,Psychosis,Brief Reactive Psychoses,Brief Reactive Psychosis,Disorder, Psychotic,Disorder, Schizoaffective,Disorder, Schizophreniform,Disorders, Psychotic,Disorders, Schizoaffective,Disorders, Schizophreniform,Psychoses, Brief Reactive,Psychotic Disorder,Reactive Psychoses, Brief,Reactive Psychosis, Brief,Schizoaffective Disorders,Schizophreniform Disorder
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005476 Fluphenazine A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE. Flufenazin,Fluphenazine Hydrochloride,Lyogen,Prolixin,Hydrochloride, Fluphenazine
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006760 Hospitalization The confinement of a patient in a hospital. Hospitalizations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

T Van Putten, and S R Marder
January 1985, Psychopharmacology bulletin,
T Van Putten, and S R Marder
January 1983, Schizophrenia bulletin,
T Van Putten, and S R Marder
November 2001, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
T Van Putten, and S R Marder
January 1988, Annales medico-psychologiques,
T Van Putten, and S R Marder
August 2010, Journal of thoracic imaging,
T Van Putten, and S R Marder
January 2002, Archives of gerontology and geriatrics. Supplement,
T Van Putten, and S R Marder
May 1974, Lakartidningen,
T Van Putten, and S R Marder
July 2000, Human psychopharmacology,
T Van Putten, and S R Marder
April 2006, The Nurse practitioner,
Copied contents to your clipboard!